BioAffinity Technologies Closes $4 Million Direct Offering, Private Placement
MT newswire2026/10/09 16:1312:13 PM EDT, 10/09/2026 (MT Newswires) -- BioAffinity Technologies (BIAF) closed a registered direct offering of common shares and prefunded warrants, along with a concurrent private placement of warrants, for about $4 million in gross proceeds. The registered direct offering was priced at $6.122 a share or $6.115 per prefunded warrant, bioAffinity said Friday in a statement. The private placement includes warrants to purchase up to 980,072 common shares at $6.122 each, exercisable after stockholder approval and expiring five years after approval. BioAffinity plans to use net proceeds for working capital, to support sales of its CyPath Lung diagnostic test, and for general corporate purposes. BioAffinity shares fell 14% in Friday trading. Price: 4.84, Change: -0.80, Percent Change: -14.15
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
